eGFR(Epidermal growth factor receptor) < 50mL/min
AST(aspartate aminotransferase)/ALT(alanine aminotransaminase) >2.5 upper limit of normal
Pregnant or lactating women
Subject who the investigator deems inappropriate to participate in this study
Patients with a history of bladder cancer or patients with active bladder cancer
Patients with uninvestigated macroscopic hematuria
Patients with cardiac failure or a history of cardiac failure (New York Heart Association [NYHA] Stages 3 to 4)
Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose

NCT02763007_exc_T1
Measurement
eGFR
NCT02763007_exc_T2
Measurement
Epidermal growth factor receptor
NCT02763007_exc_T3
Value
< 50mL/min
NCT02763007_exc_T4
Measurement
AST
NCT02763007_exc_T5
Measurement
aspartate aminotransferase
NCT02763007_exc_T6
Measurement
ALT
NCT02763007_exc_T7
Measurement
alanine aminotransaminase
NCT02763007_exc_T8
Value
>2.5 upper limit of normal
NCT02763007_exc_T9
Scope
AST(aspartate aminotransferase)/ALT(alanine aminotransaminase
NCT02763007_exc_T12
Condition
bladder cancer
NCT02763007_exc_T13
Qualifier
active
NCT02763007_exc_T14
Condition
bladder cancer
NCT02763007_exc_T15
Condition
macroscopic hematuria
NCT02763007_exc_T16
Qualifier
uninvestigated
NCT02763007_exc_T17
Condition
cardiac failure
NCT02763007_exc_T18
Observation
history of cardiac failure
NCT02763007_exc_T19
Measurement
rk Heart Association [NYHA  3 t
NCT02763007_exc_T20
Value
3 to 4
NCT02763007_exc_T21
Measurement
NYHA
NCT02763007_exc_T22
Scope
cardiac failure or a history of cardiac failure
NCT02763007_exc_T23
Condition
genetic problems
NCT02763007_exc_T24
Condition
galactose intolerance
NCT02763007_exc_T25
Condition
Lapp lactase deficiency
NCT02763007_exc_T26
Condition
glucose-galactose malabsorption
NCT02763007_exc_T27
Scope
galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption